Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company, based in Copenhagen, Denmark, that specializes in the discovery, development, and commercialization of peptide-based medicines. Its portfolio of medicines focuses on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide, a once-daily GLP-1 analogue, under the brand names of Adlyxin and Lyxumia. It also markets Dasiglucagon, a single-use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia. The company is also developing Dasiglucagon dual-hormone artificial pancreas for automated diabetes management, which is currently in Phase III clinical trials.

In addition, Zealand Pharma A/S is developing glepaglutide, a long-acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company has collaborated with a number of organizations, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.

Zealand Pharma A/S was incorporated in 1998 and is led by Chief Executive Officer Britt Meelby Jensen. Its Board of Directors consists of seven members, including Chairman of the Board Bo Jesper Hansen, and the company employs over 130 people. It is listed on the Nasdaq Copenhagen Stock Exchange and has a market capitalization of approximately US$2.3 billion.